These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6143225)

  • 1. Double-blind placebo-controlled trial of naloxone on motor deficits in acute cerebrovascular disease.
    Perraro F; Tosolini G; Pertoldi F; Sbrojavacca R; Beorchia A; Bulfoni A; Del Fabbro L; Grassi L; Lestuzzi A; Mione V
    Lancet; 1984 Apr; 1(8382):915. PubMed ID: 6143225
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of naloxone on acute stroke.
    Czlonkowska A; Cyrta B
    Pharmacopsychiatry; 1988 Mar; 21(2):98-100. PubMed ID: 3293092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double blind trial of naloxone in the treatment of acute stroke.
    Fallis RJ; Fisher M; Lobo RA
    Stroke; 1984; 15(4):627-9. PubMed ID: 6087500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke.
    Federico F; Lucivero V; Lamberti P; Fiore A; Conte C
    Ital J Neurol Sci; 1991 Dec; 12(6):557-63. PubMed ID: 1783533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind trial of naloxone in central post-stroke pain.
    Bainton T; Fox M; Bowsher D; Wells C
    Pain; 1992 Feb; 48(2):159-162. PubMed ID: 1589232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical, rheoencephalographic and ophthalmodynamographic double-blind studies of the effects of vincamine in the treatment of cerebrovascular diseases].
    Kauchtschischvili G; Nappi G; Bono G
    Minerva Med; 1974 May; 65(40):2296-315. PubMed ID: 4608671
    [No Abstract]   [Full Text] [Related]  

  • 8. Naloxone effectiveness on spontaneous and induced perceptive disorders in migraine.
    Sicuteri F; Boccuni M; Fanciullacci M; Gatto G
    Headache; 1983 Jul; 23(4):179-83. PubMed ID: 6350225
    [No Abstract]   [Full Text] [Related]  

  • 9. Naloxone fails to reverse blood pressure in shock: a double blind study in man.
    Montastruc JL; Richard JP; Cathala B
    J Pharmacol; 1985; 16(3):313-4. PubMed ID: 3906280
    [No Abstract]   [Full Text] [Related]  

  • 10. Naloxone in tardive dyskinesia.
    Blum I; Nisipeanu PF; Roberts E
    Psychopharmacology (Berl); 1987; 93(4):538. PubMed ID: 3124188
    [No Abstract]   [Full Text] [Related]  

  • 11. Low- and high-dose naloxone in dementia of the Alzheimer type.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Cohen MR; Cohen RM
    Psychopharmacol Bull; 1985; 21(3):680-2. PubMed ID: 3898183
    [No Abstract]   [Full Text] [Related]  

  • 12. Naloxone fails to counteract heavy alcohol intoxication.
    Nuotto E; Palva ES; Lahdenranta U
    Lancet; 1983 Jul; 2(8342):167. PubMed ID: 6135014
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
    Bracken MB; Shepard MJ; Collins WF; Holford TR; Young W; Baskin DS; Eisenberg HM; Flamm E; Leo-Summers L; Maroon J
    N Engl J Med; 1990 May; 322(20):1405-11. PubMed ID: 2278545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of naloxone to reverse analgesia in congenital insensitivity to pain, and variable plasma levels of beta-endorphin-like activity.
    Pasi A; Meyer M; Boltshauser E; Foletta D; Gramsch C
    Lancet; 1982 Mar; 1(8272):622. PubMed ID: 6174837
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
    Simpson GM; Yadalam KG; Stephanos MJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Problems in the long-term medical treatment of sequelae of acute cerebrovascular diseases. Double-blind studies].
    Agnoli A
    Minerva Med; 1976 May; 67(26):1719-26. PubMed ID: 934526
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
    Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
    Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone versus placebo in treatment of septic shock.
    DeMaria A; Carven DE; Heffernan JJ; McIntosh TK; Grindlinger GA; McCabe WR
    Lancet; 1985 Jun; 1(8442):1363-5. PubMed ID: 2861315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A double-blind comparison of a sulfurated mucopolysaccharide and placebo in the treatment of elderly patients with cerebrovascular insufficiency].
    Astengo F; Fontana L; Balestreri R
    Clin Ter; 1987 Feb; 120(3):219-26. PubMed ID: 2461828
    [No Abstract]   [Full Text] [Related]  

  • 20. [Methodology of a controlled trial of dihydroergotoxine in acquired intellectual impairment in the adult].
    Dartigues JF; Père JJ
    Presse Med; 1983 Dec; 12(48):3173-5. PubMed ID: 6228936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.